Dr. Osama Mohamad received his undergraduate degree at the American University of Beirut, in Beirut, Lebanon in 2006 with the highest honors. He then enrolled in the medical scientist training program (MSTP) at Emory University in Atlanta, and successfully finished his MD Ph.D. (Ph.D. in stem cells and regenerative medicine) in 2014. During his Ph.D., he received a Howard Hughes Medical Institute Fellowship award and completed a certificate program in clinical and translational research. He completed a transitional year internship at the University of Hawaii (where he received the resident of the year award), then finished residency training in radiation oncology at the University of Texas Southwestern (UTSW) Medical Center, in Dallas (where he was a chief resident). During residency, he spent a year pursuing a research fellowship at the National Institute of Radiological Sciences in Japan studying carbon ion radiotherapy for prostate cancer. Over his years in training, he received many awards including the resident of the year award and the RSNA Roentgen research award during his chief resident year at UTSW. He presented his research at multiple national and international meetings and published over 45 publications.

Dr. Mohamad’s number one priority is his patients. He is interested in healthcare innovation with a focus on oncology. He is passionate about clinical care and bringing cutting-edge research and innovation to his patients. At UCSF, he will be treating genitourinary cancers with a special focus on prostate and kidney cancers using intensity-modulated radiotherapy (IMRT), stereotactic radiotherapy (SBRT), and HDR brachytherapy. He will build on the strong interdisciplinary cancer clinical programs in the departments of urology, radiation oncology, and medical oncology at UCSF to develop clinical research, clinical trials, and translational research in prostate and kidney cancers.

Osama Mohamad

University of California, San Francisco

Topic: Will Artificial Intelligence Ever Substitute for Pathologists?